Author

Ivana Gojo

Johns Hopkins UniversityORCID 0000-0003-0312-3412Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Amy Elizabeth DezerniD· 2 shared Bogdan C. Paun· 2 shared Brandy N. Perkins· 2 shared Linda M S ResariD· 2 shared Mark J. LevisiD· 2 shared Nour Sabiha NajiiD· 2 shared Styliani KaranikaiD· 2 shared Suman PauliD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Amy Elizabeth DezernORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 17, 2025

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML

Nour Sabiha Naji, Taha S. Ahmedna, J. David Peske…·Theodoros Karantanos

This paper develops an anti-CCRL2 antibody-drug conjugate (ADC) that shows potent cytotoxicity against high-risk MDS/AML cells without harming healthy hematopoietic cells.

1 citation

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 21, 2025

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53

Nour Sabiha Naji, Sergiu Paşca, Theodora Chatzilygeroudi…·Theodoros Karantanos

This study identifies CCRL2 as a driver of IFN-γ signaling in TP53-mutated AML with erythroid differentiation, linking it to disease progression and poor outcomes.

2 citations

humanproteomics

𝕏 PostBluesky